The finding that pancreatic cancer cells with acquired resistance to 5-FU show increased expression of L1CAM, in addition to the distinction of L1CAM presence in cancerous vs. normal tissues [52], makes us hopeful that targeting of L1CAM with therapeutic antibodies and/or in combination with 5-FU could potentially benefit selected patients with refractory pancreatic tumors. The gene discussed is L1CAM; the disease is pancreatic neoplasm.